GLEAMER
Acquired by
RADNET
GLEAMER acquired by RADNET
Target
GLEAMER
Acquirer
RADNET
Context
RadNet acquired Gleamer in an all-cash transaction to integrate its automated diagnostic and reporting solutions into the DeepHealth platform. The acquisition aims to create the world's largest provider of clinical radiology AI solutions by combining RadNet's massive US imaging volume with Gleamer's advanced multi-modality software. Gleamer will now operate as RadNet’s French subsidiary, with founder Christian Allouche continuing to lead development from Paris. The strategic goal is to automate routine imaging workflows—specifically plain-film X-rays, which represent 25% of RadNet’s volume—to drive significant cost efficiencies and diagnostic accuracy.
Target
Gleamer is a leading French MedTech company specializing in artificial intelligence for medical imaging. Its "Copilot" platform provides automated diagnostic assistance for radiologists across multiple modalities, including X-ray, Mammography, and MRI. Prior to this acquisition, Gleamer consolidated the market by acquiring Pixyl and Caerus Medical in 2025, expanding its expertise into neuro and lumbar MRI. The company serves over 700 clients in 44 countries, with its solutions supporting over 25 clinical indications.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
N/A
EV / EBITDA
N/A
EV / EBIT
N/A
Historical Financials (EUR)
Sign in to access transaction multiples for GLEAMER's acquisition by RADNET.
Other operations with GLEAMER
| Date | Target | Country | Sector | Target Description | Acquirer |
|---|---|---|---|---|---|
| 06/2023 | GLEAMER | FRANCE | Healthcare Services | Gleamer is a leading French MedTech company specializing in artificial intelligence for medical imaging. Its "Copilot" platform provides automated diagnostic assistance for radiologists across multiple modalities, including X-ray, Mammography, and MRI. Prior to this acquisition, Gleamer consolidated the market by acquiring Pixyl and Caerus Medical in 2025, expanding its expertise into neuro and lumbar MRI. The company serves over 700 clients in 44 countries, with its solutions supporting over 25 clinical indications. | SUPERNOVA INVEST / HEAL CAPITAL |